lobeglitazone
Small moleculeexperimental
Lobeglitazone is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. — Wikipedia
Clinical trial activity
48 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
36
Phase 2
7
Phase 3
6
Phase 4
5
Earliest trial started Jul 1, 2007 (NCT01030679)
Timeline
Indications
Approved for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1- Mol. weight
- 480.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLobeglitazone ↗
- ChEMBLCHEMBL3585580 ↗
Also known as
- ckd501
- ckd 501
- ckd-501
- ckd-501
- ckd-501
- ckd-501
- duvie
- lobeglitazone
- lobeglitazone
- lobeglitazone
- lobeglitazone
- lobeglitazone
- lobeglitazone
- lobeglitazone
- lobeglitazone sulfate
- lobeglitazone sulfate
- lobelitazone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07304726 | Phase 1 | Oct 30, 2025 | Chong Kun Dang Pharmaceutical |
| NCT07304700 | Phase 1 | Oct 28, 2025 | Chong Kun Dang Pharmaceutical |
| NCT07304687 | Phase 1 | Oct 24, 2025 | Chong Kun Dang Pharmaceutical |
| NCT07056517 | Phase 1 | Jul 11, 2025 | — |
| NCT06695598 | Phase 1 | Nov 6, 2024 | Chong Kun Dang Pharmaceutical |
| NCT06695572 | Phase 1 | Nov 6, 2024 | Bumin Hospital, Chong Kun Dang Pharmaceutical |
| NCT06492655 | Phase 1 | Jul 4, 2024 | Chong Kun Dang Pharmaceutical, Seoul National University |
| NCT06483243 | Phase 1 | Apr 4, 2024 | Chong Kun Dang Pharmaceutical, Chung-Ang University |
| NCT05897216 | Phase 1 | Jun 15, 2023 | Cha Medical University, Chong Kun Dang Pharmaceutical |
| NCT05816759 | Phase 1 | Apr 28, 2023 | Cha Medical University, Chong Kun Dang Pharmaceutical |
| NCT05566028 | Phase 3 | Oct 1, 2022 | Chong Kun Dang Pharmaceutical, Seoul National University |
| NCT05274880 | Phase 1 | Jun 21, 2022 | Chong Kun Dang Pharmaceutical, Korea University |
| NCT05347576 | Phase 1 | Apr 21, 2022 | Chonbuk National University, Chong Kun Dang Pharmaceutical |
| NCT05915949 | Phase 4 | Jan 1, 2022 | Seoul National University |
| NCT05113693 | Phase 1 | Nov 3, 2021 | Chonbuk National University, Chong Kun Dang Pharmaceutical |
| NCT04869800 | Phase 1 | May 27, 2021 | Chong Kun Dang Pharmaceutical |
| NCT04810676 | Phase 1 | Apr 16, 2021 | Chong Kun Dang Pharmaceutical, Yonsei University |
| NCT04768673 | Phase 1 | Mar 26, 2021 | Chong Kun Dang Pharmaceutical, Yonsei University |
| NCT04706286 | Phase 1 | Feb 18, 2021 | Chong Kun Dang Pharmaceutical, Yonsei University |
| NCT04431687 | Phase 1 | Jun 15, 2020 | Cha Medical University, Chong Kun Dang Pharmaceutical |
Showing 20 of 48 trials
Page 1 / 3
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | For profit | 44 | 43 | 4 | 2007 |
| Yonsei University | Academic/Hospital | 11 | 1 | 3 | 2011 |
| Korea University | Academic/Hospital | 6 | 0 | 4 | 2007 |
| Chonbuk National University | Academic/Hospital | 5 | 0 | 1 | 2015 |
| Seoul National University | Academic/Hospital | 5 | 2 | 3 | 2009 |
| Cha Medical University | Academic/Hospital | 3 | 0 | 1 | 2020 |
| Bumin Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Chung-Ang University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Inje University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Kangbuk Samsung Hospital | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Pusan National University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2013 |
13 organizations
Page 1 / 1